Drugs / Cadisegliatin
Trials 4 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT03335371 | Oct 2017 → Dec 2019 | type 1 diabetes mellitus | vTv Therapeutics | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT07616206 | Jul 2026 → Apr 2027 expected | type 1 diabetes mellitus | vTv Therapeutics | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT02405260 | Mar 2015 → Jul 2016 | type 2 diabetes mellitus | vTv Therapeutics | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT06334133 | Jun 2024 → Sep 2026 expected | type 1 diabetes mellitus | vTv Therapeutics | Recruiting | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Cadisegliatin | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07616206 ↗ |
| Known as | TTP399 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02405260 ↗ |
| Action | Activate | “Add Glucokinase Activator to Target A1c” NCT02405260 ↗ |
| Modality | Small molecule | “orally bioavailable small-molecule glucokinase activator” NCT06334133 ↗ |
| Route | Oral | “TTP399 administered orally up to 1200 mg taken once daily for 7 days” NCT03335371 ↗ |